|
|
||||||||
2 Cardiology Section, Department of Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado 80220; and 1 Cardiovascular Research Institute, University of California, San Francisco, California 94121
| |
ABSTRACT |
|---|
|
|
|---|
Clinical and experimental
studies have suggested benefit of treatment with intravenous
glucose-insulin-potassium (GIK) in acute myocardial infarction.
However, patients hospitalized with acute coronary syndromes often
experience recurrent myocardial ischemia without infarction
that may cause progressive left ventricular (LV) dysfunction. This
study tested the hypothesis that anticipatory treatment with GIK
attenuates both systolic and diastolic LV dysfunction resulting from
ischemia and reperfusion without infarction in vivo.
Open-chest, anesthetized pigs underwent 90 min of moderate regional
ischemia (mean subendocardial blood flow 0.3 ml · g
1 · min
1)
and 90 min reperfusion. Eight pigs were treated with GIK (300 g/l
glucose, 50 U/l insulin, and 80 meq/l KCl; infused at 2 ml · kg
1 · h
1)
beginning 30 min before ischemia and continuing through
reperfusion. Eight untreated pigs comprised the control group. Regional
LV wall area was measured with orthogonal pairs of sonomicrometry crystals. GIK significantly increased myocardial glucose uptake and
lactate release during ischemia. After reperfusion, indexes of
regional systolic function (external work and fractional systolic wall
area reduction), regional diastolic function (maximum rate of diastolic
wall area expansion), and global LV function (LV positive and negative
maximum rate of change in pressure with respect to time) recovered to a
significantly greater extent in GIK-treated pigs than in control pigs
(all P < 0.05). The findings suggest
that the clinical utility of GIK may extend beyond treatment of acute
myocardial infarction to anticipatory metabolic protection of
myocardium in patients at risk for recurrent episodes of ischemia.
ventricular function; energy metabolism; substrates
| |
INTRODUCTION |
|---|
|
|
|---|
INTERVENTIONS THAT ENHANCE the availability and utilization of glucose by the ischemic heart may attenuate ischemic injury and postischemic ventricular dysfunction (7). A mixture of glucose, insulin, and potassium (GIK) was first shown to limit electrocardiographic changes in acute myocardial infarction by Sodi-Pallares and colleagues in 1962 (33). Subsequent experimental studies demonstrated a salutary effect of GIK in limiting infarct size and improving recovery of mechanical function in models of myocardial infarction (1, 21, 27). Initial clinical trials in the 1960s and 1970s suggested that GIK reduced morbidity and mortality in acute myocardial infarction (3, 22, 29, 31), but the results were inconclusive. For the most part, the potential therapeutic utility of GIK was ignored for two succeeding decades.
Recently, there has been a resurgence of interest in GIK as a treatment for patients with acute myocardial infarction. In a meta-analysis of nine prior clinical studies, Fath-Ordoubadi and Beatt (10) came to the remarkable conclusion that GIK reduced in-hospital mortality from acute myocardial infarction by 28%. The magnitude of this mortality reduction is comparable to that achieved with thrombolytic therapy and suggests that metabolic protection of ischemic myocardium may be as important as reperfusion itself. The DIGAMI study (20) in diabetic patients showed that insulin-glucose infusion early in the course of acute myocardial infarction, followed by a multidose insulin regimen, reduced mortality compared with conventional therapy. In a multicenter study in acute myocardial infarction (8), treatment with GIK and a concurrent reperfusion strategy resulted in a 34% reduction in mortality compared with a control group of patients who did not receive GIK. GIK has also been shown to be effective in improving cardiac function after cardiopulmonary bypass and cardioplegic arrest (16, 24).
Despite the renewed interest in GIK as a clinical intervention in acute myocardial infarction, there is a paucity of data regarding the utility of GIK in acute myocardial ischemia without infarction. Patients hospitalized with acute coronary syndromes frequently experience recurrent episodes of myocardial ischemia without infarction that may cause progressive left ventricular (LV) dysfunction. Such patients may therefore benefit from a strategy of anticipatory metabolic protection. Indeed, when isolated, perfused hearts are subjected to moderate ischemia followed by reperfusion, the addition of extra glucose and insulin to the perfusate attenuates both contractile and lusitropic dysfunction (2, 9). To date, however, there have been no analogous data from in vivo models.
Beneficial effects of GIK in myocardial ischemia may result from increased myocardial glucose uptake and glycogen content, providing additional substrate for glycolytic energy generation. Benefit may also be due to reduced circulating levels and myocardial uptake of free fatty acids (FFA; see Ref. 28). However, there are at least two theoretical reasons why GIK might exert deleterious effects during ischemia. First, incremental myocardial glucose uptake due to GIK may result in increased glycogen synthesis (energy consuming) and/or increased glycolysis (energy producing). If, during ischemia, the rate of glycogen synthesis is increased to a greater extent than the rate of glycolysis (13), the net energetic consequence could be unfavorable. Second, glycolysis results in formation of protons, whose accumulation may promote intracellular calcium overload and reperfusion injury. Provision of additional glycolytic substrate during ischemia could exacerbate this mechanism of injury.
This study tested the hypothesis that anticipatory treatment with GIK attenuates both systolic and diastolic dysfunction resulting from myocardial ischemia and reperfusion without infarction in an intact, porcine model.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Experimental preparation. All
experiments were performed in accordance with the
Guide for the Care and Use of Laboratory
Animals of the United States National Institutes of
Health. The experimental preparation and instrumentation of the heart
have been described previously (32, 37). Nineteen female
Yorkshire-Landrace pigs, weighing 28-38 kg, were premedicated with
ketamine hydrochloride (25 mg/kg im). Anesthesia was induced with 100 mg/kg iv
-chloralose and was maintained with 40 mg · kg
1 · h
1
iv
-chloralose. After endotracheal intubation via a tracheotomy, pigs were mechanically ventilated with an air-oxygen mixture. Respiratory rate and tidal volume were adjusted on the basis of frequent arterial blood gas analyses. To prevent hypothermia, pigs were
wrapped in recirculating warm water blankets and insulated pads.
Indomethacin (25 mg iv) was given to prevent subsequent hemodynamic
response to the injection of fluorescent microspheres suspended in
diluted Tween solution. Propranolol (1 mg/kg iv) and atropine (0.2 mg/kg iv) were given to prevent activation of autonomic reflexes.
Figure 1 shows the instrumentation of the
heart. The chest was opened via a median sternotomy. A bipolar pacing
electrode was affixed to the left atrial appendage and was used to
maintain heart rate slightly above the spontaneous rate. Fluid-filled
catheters were inserted in the aortic arch via a carotid artery and in
the left atrium via its appendage. A 5-Fr Millar catheter (Millar Instruments, Houston, TX) was inserted in the LV cavity through a
carotid artery. To produce dynamic alteration in preload, hydraulic cuff occluders (In Vivo Metric, Healdsburg, CA) were placed around the
inferior and superior venae cavae. A segment of the left anterior descending coronary artery (LAD) between its first and second diagonal
branches was dissected free of surrounding tissue. An ultrasonic
transit time flow probe (Transonic Systems, Ithaca, NY) was placed
around the vessel to monitor coronary flow. A hydraulic cuff occluder
was placed just distal to the flow probe to produce graded myocardial
ischemia. To obtain coronary venous blood samples from the
ischemic region, a catheter was inserted in the anterior interventricular vein at a site distal to that of the LAD occluder, with the tip of the catheter directed toward the apex of the heart. Regional LV function was measured in the central portion of the anterior free wall (ischemic region) and in the posterolateral free
wall (nonischemic region). In each region, an array of four sonomicrometry crystals (2 orthogonal pairs) was implanted in the
subendocardium. Each crystal array was used to calculate regional myocardial wall area as the instantaneous product of the two orthogonal segment lengths (17).
|
Myocardial blood flow, oxygen consumption, and substrate uptake. Transmural myocardial blood flow measurements were made under each experimental condition using left atrial injection of fluorescent microspheres, as previously described (32). Oxygen, glucose, lactate, and FFA contents were measured in paired arterial and anterior interventricular venous blood samples, as previously described (32, 35). Uptakes of each of these substances by the anterior LV free wall were calculated as the product of the mean transmural blood flow and the coronary arteriovenous concentration difference. In pigs, at least 90% of anterior interventricular venous blood is derived from myocardium perfused by the LAD, even under ischemic conditions (4). Insulin and potassium were measured in arterial plasma by RIA and potentiometry, respectively.
Experimental protocol. The following
four sets of measurements were made in each pig: baseline, preischemic
treatment, ischemia, and reperfusion. After a 30-min period of
stabilization, baseline measurements of hemodynamics, regional LV
function, myocardial blood flow, myocardial oxygen and substrate
uptake, and plasma insulin and potassium were obtained. Pigs were then
alternately assigned to one of two groups. The control group
(n = 8) received an intravenous
infusion of normal saline (2 ml · kg
1 · h
1),
whereas the GIK group (n = 8) received
an intravenous infusion of GIK (glucose: 300 g/l; insulin: 50 U/l;
potassium: 80 meq/l) infused at 2 ml · kg
1 · h
1.
The infusions were continued for the remaining duration of the experimental protocol. After saline or GIK had been infused for 30 min
under nonischemic conditions, the second set of measurements was
obtained (preischemic treatment). Low-flow ischemia was then induced by gradual inflation of the LAD occluder until LAD flow rate
(monitored by the transit-time flowmeter) was reduced to 50% of
baseline. This degree of constriction was then maintained for 90 min;
slight adjustments of the coronary occluder were made as necessary to
maintain constant 50% reduction of LAD flow. We have previously shown
that regional ischemia of this severity and duration in this
model results in a reproducible reduction of subendocardial blood flow
and regional external work to 25-35% of baseline, without
histochemical or electron micrographic evidence of myocardial
infarction (19). Between 60 and 90 min of ischemia, the third
set of measurements was obtained. After 90 min ischemia, the
coronary occluder was released. The fourth and final set of measurements was performed between 60 and 90 min of reperfusion. The
control group of this study also served as the control group for
another contemporaneous study (37).
After euthanasia, transmural specimens of myocardium were excised from ischemic and nonischemic regions of the LV for analysis of regional blood flow. In addition, a transmural sample of myocardium from the center of the ischemic region was incubated in warm 1% triphenyltetrazolium chloride (TTC) for 20 min and was examined for evidence of nonstaining indicative of myocardial infarction (11).
Hemodynamic data collection and analysis of ventricular function. Hemodynamic and sonomicrometry data were digitized and analyzed as previously described (19, 37). Data were collected both under steady-state hemodynamic conditions and during brief occlusion of the venae cavae with temporary suspension of mechanical ventilation. At least five sets of data were collected under each experimental condition.
LV pressure versus wall area loops were analyzed. The area of each loop
was used as an index of the regional external work performed in that
cardiac cycle. Steady-state regional external work was calculated as
the average loop area recorded without occlusion of the venae cavae.
Regional preload recruitable stroke work (PRSW) relations (12) were
determined during brief occlusion of the venae cavae by plotting the
area of each LV pressure versus wall area loop against its
corresponding end-diastolic wall area. End diastole was defined by the
initial upstroke of an intramyocardial electrogram recorded using the
intramyocardial electrocardiogram capability of the sonomicrometer.
PRSW slope and interecept were determined by linear regression. Because
regional wall area depends in part upon how far apart each pair of
crystals is implanted (i.e., a source of experimental rather than
physiological variability), external work and PRSW data were normalized
to their baseline values in each experiment. Systolic function was also
assessed by fractional systolic wall area reduction (FAR), a
two-dimensional analog to fractional systolic segment shortening,
calculated as
|
Regional LV relaxation was assessed by the maximum rate of wall area
expansion (peak positive
dA/dt
or
+dA/dtmax)
occurring during early diastole. This is a regional analog to peak LV
filling rate.
+dA/dtmax
was normalized to baseline in each experiment. Passive diastolic
properties were assessed by examining LV end-diastolic pressure versus
regional wall area relations, using a monoexponential curve-fitting
technique described previously (19). Global LV relaxation was assessed
by peak negative LV dP/dt
(
dP/dtmax).
Statistical analysis. To determine if the response of a variable differed between groups during the experimental protocol, two-way repeated-measures ANOVA was employed, followed by unpaired t-tests to compare the value of the variable between groups under specific experimental conditions. To determine the significance of changes in a variable between baseline and subsequent conditions within the same group, one-way repeated-measures ANOVA was employed, followed by Dunnett's procedure. Data are expressed as means ± SE. Statistical analysis was performed using SigmaStat software (Jandel Scientific, San Rafael, CA).
| |
RESULTS |
|---|
|
|
|---|
Three pigs sustained ventricular fibrillation during ischemia (2 in the control group and 1 in the GIK group) and were not resuscitated. Hemodynamic and metabolic data from 16 pigs that completed the experimental protocol (8 in each group) are reported below.
Regional myocardial blood
flow. During ischemia, total LAD
flow (measured by the ultrasonic flow probe) was regulated to maintain a 50% reduction from baseline. This degree of flow reduction was associated with moderate anterior LV subendocardial ischemia
(~25% of baseline perfusion) and milder subepicardial
ischemia (~60% of baseline perfusion) as indicated in Table
1. Perfusion of the posterior LV did not
change significantly throughout the experimental protocol. There were
no significant differences between groups in either LAD blood flow or
regional myocardial perfusion under any experimental condition.
Incubation of myocardium from the ischemic region in TTC resulted in
homogeneous, transmural red staining, consistent with the absence of
myocardial infarction.
|
Circulating substrate and insulin levels and substrate
uptake of the anterior LV. At baseline, there were no
significant differences between groups in arterial substrate, insulin,
or potassium concentrations, myocardial substrate uptake, or oxygen
consumption (Table 2). Infusion of GIK
increased arterial glucose and insulin concentrations, decreased
arterial FFA concentration, and did not alter plasma potassium
concentration. GIK significantly increased anterior LV glucose uptake
during both preischemic treatment and ischemia (Fig.
2). During ischemia, there was net
lactate release in both groups; however, the GIK-treated group released
significantly more lactate, indicating enhanced anaerobic glycolysis
(Fig. 3). There was a trend to diminished
myocardial FFA uptake with GIK during both preischemic treatment and
ischemic periods; however, this trend did not achieve statistical
significance (Fig. 4). Anterior LV oxygen
consumption declined during ischemia and remained reduced
during reperfusion, but there were no significant differences between
groups. During ischemia, the coronary arteriovenous pH difference (reflecting transmyocardial production of hydrogen ions) was
significantly greater in the GIK group than in the control group,
consistent with a higher rate of anaerobic glycolytic metabolism. During reperfusion, the coronary arteriovenous pH difference returned to baseline in both groups (Table 2).
|
|
|
|
Regional systolic function.
Administration of GIK during the preischemic treatment period had no
discernible effect on indexes of regional systolic function. As
expected, indexes of systolic function in the anterior LV declined
during ischemia and remained depressed during reperfusion in
both groups. However, GIK-treated pigs demonstrated significantly
greater recovery of systolic function with reperfusion (Fig.
5). Both steady-state regional external work and FAR recovered to significantly greater values in the GIK
group. For example, regional external work recovered to a mean level
38% of baseline with GIK but only to 18% of baseline in the control
group. Similarly, FAR recovered to 38% of baseline in the GIK group
but to only 4% of baseline in the control group. The improved recovery
of systolic function with GIK was not attributable to a difference in
loading conditions, since end-diastolic wall area (preload) and aortic
systolic pressure did not differ between groups (Table
3). Analysis of anterior LV PRSW relations
also revealed a beneficial effect of GIK. After reperfusion, PRSW slope (the increment in regional external work for a given increment in
preload) recovered to 81 ± 7% of baseline in the GIK group compared with 61 ± 5% of baseline in the control group
(P < 0.05). However, there was no
difference between groups in PRSW intercept, which increased
significantly with ischemia and remained increased from
baseline during reperfusion. The effects of anterior LV
ischemia on systolic function of the posterior LV were minor
and did not differ significantly between groups (Table 3).
|
|
|
Regional diastolic function.
Administration of GIK during the preischemic treatment period had no
discernible effect on indexes of regional diastolic function. In the
control group during both ischemia and reperfusion, the maximum
rate of diastolic wall area expansion
(+dA/dtmax)
was reduced in the anterior LV. The duration of early diastolic wall
expansion was shortened, and early systolic wall area expansion was
prominent. In contrast in the GIK-treated group,
+dA/dtmax
did not change significantly between baseline and ischemia and
remained significantly greater than in the control group during both
ischemia and reperfusion (Fig. 6, Table 3). Furthermore, the
duration of early diastolic wall area expansion remained longer, and
early systolic wall expansion was less prominent compared with the
control group (Fig. 6). The beneficial
effect of GIK on early diastolic wall expansion was not attributable to
a difference in left atrial driving pressure, which did not differ
between groups. Treatment with GIK did not alter the effects of
ischemia and reperfusion on passive (end-diastolic) LV pressure versus wall area relations. In both groups, these relations shifted to
the right compared with baseline at low LV end-diastolic pressures (0-3 mmHg) and became steeper (stiffer) compared with baseline at
higher end-diastolic pressures. Neither early nor late diastolic function of the posterior (nonischemic) LV changed significantly under
any of the experimental conditions in either group (Table 3).
|
Global LV function: LV end-diastolic
pressure was elevated during ischemia and reperfusion in both
groups. During ischemia, LV
+dP/dtmax fell
significantly in the control group but not in the GIK group. With
reperfusion, LV +dP/dt and
dP/dtmax remained significantly greater in the GIK group than in the control group (Table
4), suggesting that global LV contractility was better preserved with
GIK. LV
dP/dtmax
decreased during ischemia in both groups and remained reduced
from baseline during reperfusion; however, the values of LV
dP/dtmax
during ischemia and reperfusion remained significantly greater
in GIK pigs (Table 4), indicating that abnormal LV relaxation was
mitigated by GIK. Interpretation of changes in LV
dP/dt depends upon concurrent loading
conditions. Although LV end-diastolic volume and systolic wall stress
were not measured, surrogate measures of preload and afterload (LV end-diastolic pressure and peak systolic pressure) did not differ between groups. Thus the data indicate that GIK helped to preserve global LV systolic and diastolic function in parallel with its salutary effects on regional function of the ischemic zone.
| |
DISCUSSION |
|---|
|
|
|---|
New findings of this study. This study
demonstrates that infusion of GIK exerts salutary effects on LV
function during and after ischemia without infarction in vivo.
These effects were determined using rigorous methods to analyze
regional LV function. Both regional systolic function (external work,
FAR, and PRSW slope) and diastolic function (maximal rate of diastolic
wall area expansion) were better preserved during ischemia and
reperfusion in GIK-treated pigs compared with untreated pigs.
Furthermore, these effects were paralleled by higher values of LV
+dP/dtmax and
dP/dtmax
after ischemia and reperfusion, implying improved recovery of
global LV contractility and relaxation. These findings suggest that the
clinical utility of GIK may extend beyond its prior application in
acute myocardial infarction (8, 10) to the treatment of episodic
myocardial ischemia and unstable coronary syndromes.
Effects of GIK on myocardial substrate metabolism. The effects of GIK on myocardial substrate metabolism were examined during preischemic, ischemic, and reperfusion periods. In the preischemic period, GIK-treated hearts demonstrated increased glucose uptake, a trend to decreased FFA uptake, and no difference in lactate uptake compared with untreated hearts. Approximately two-thirds of the additional glucose uptake by GIK-treated hearts can be explained by a shift in oxidative substrate from FFA to glucose, since oxidation of 4 mol of glucose consumes as much oxygen as oxidation of 1 mol of FFA, and oxygen consumption did not differ between groups. The remainder of the increased preischemic glucose uptake by GIK-treated hearts was likely used for synthesis and accumulation of additional myocardial glycogen (15). In isolated, perfused hearts, a high preischemic glycogen content has been associated with improved functional recovery from moderate myocardial ischemia (6), and this may be a mechanism of benefit of GIK in the current study.
During ischemia, myocardial glucose uptake in GIK-treated pigs
was greater than that in untreated pigs by an average of 0.42 µmol · g
1 · min
1.
Approximately two-thirds of this difference (0.27 µmol · g
1 · min
1)
may be explained by increased anaerobic glycolysis (i.e., nonoxidative metabolism of glucose to lactate), based on the observation that mean
lactate release from the ischemic myocardial region was 0.54 µmol · g
1 · min
1
greater in GIK-treated pigs than in untreated pigs (0.75 vs. 0.21 µmol · g
1 · min
1)
and that 2 mol of lactate are produced from 1 mol of glucose through glycolysis.
The effect of GIK on myocardial ATP synthesis during ischemia
can be estimated as follows. Each mole of net lactate release is
associated with 1 mol of ATP synthesis by anaerobic glycolysis. Accordingly, anaerobic ATP production during ischemia can be
estimated at 0.75 µmol · g
1 · min
1
in GIK-treated pigs and 0.21 µmol · g
1 · min
1
in untreated pigs. Furthermore, assuming that 6 mol of ATP are synthesized for every mole of oxygen consumed, the contribution of
anaerobic ATP production to total transmural ATP production averaged
8% in GIK-treated pigs but only 2% in untreated pigs. In the
subendocardium, the relative contribution of anaerobic ATP production
is likely to have been even greater. ATP production by anaerobic
glycolysis may help to maintain vital cellular processes during
ischemia. In ischemic isolated perfused hearts, the incremental ATP production facilitated by supplemental glucose and insulin attenuates the decline of myocardial high-energy phosphates and leads
to improved postischemic recovery of contractile function (9).
Furthermore, glycolytic ATP production during ischemia may play
an important role in maintaining LV relaxation by limiting intracellular calcium accumulation (36).
Approximately one-third of the difference in glucose uptake between GIK-treated and untreated hearts during ischemia cannot be accounted for by increased anaerobic glycolysis and lactate release and is most likely explained by increased oxidation of glucose in lieu of FFA and/or by increased glycogen synthesis. A beneficial effect of GIK due to one or more of the above mechanisms was evident before reperfusion, since end-ischemic indexes of regional and global systolic and diastolic LV function were significantly better in GIK-treated pigs than in untreated pigs.
During reperfusion, GIK did not affect the pattern of myocardial substrate uptake or oxygen consumption. In both groups, glucose uptake was greater than baseline, but net lactate uptake was much less than baseline. These findings imply a persistently increased rate of lactate production from anaerobic glycolysis despite normal myocardial perfusion and oxygen delivery and are consistent with previous observations that glucose oxidation is impaired in reperfused myocardium (18). Although interventions that stimulate glucose oxidation in reperfused hearts have been shown to improve functional recovery (18), the lack of any effect of GIK on substrate uptake or oxygen consumption during reperfusion suggests that this was not the mechanism of benefit of GIK in the current study.
Accumulation of fatty acyl metabolites during ischemia may be toxic to cardiac myocytes, causing mitochondrial damage and alterations in membrane ion channels (26). One of the potential salutary effects of GIK is an insulin-mediated reduction in circulating FFA concentrations, with consequent reduction in myocardial FFA uptake (30). In this porcine model, baseline levels of circulating FFA are low (mean arterial plasma concentration 0.3 µmol/ml) compared with mean values of ~0.8 µmol/ml in healthy human volunteers (14). Nonetheless, GIK caused significant reductions in arterial FFA concentration in our model (to ~0.1 µmol/ml) and a trend toward reduced FFA uptake during ischemia. Therefore, it is possible that reduced uptake of FFA during ischemia contributed to the beneficial effects of GIK on regional LV function in this model.
Increased myocardial acidosis due to accelerated glycolytic generation of hydrogen ions is a potential concern over the use of GIK in myocardial ischemia (6). Although intracellular pH was not measured in the current study, coronary venous pH was lower and the coronary arteriovenous pH difference was significantly greater in the GIK group than in the control group during ischemia. Therefore, improved systolic and diastolic LV function with GIK occurred despite increased myocardial hydrogen ion generation during ischemia.
Insulin has been purported to increase cardiac output and exert direct positive inotropic effects in some experimental models (34). Administration of GIK before the onset of ischemia enabled us to determine if such direct inotropic effects were evident in this model. We found no discernible effects of GIK on either systolic or diastolic LV function during the preischemic treatment period. Therefore, the improvement in postischemic function with GIK cannot be attributed to a direct inotropic effect of insulin.
Limitations. Postischemic LV dysfunction is generally more severe in anesthetized, open-chest animals than in conscious animals (5). The protective effect of GIK may also depend on these conditions. Pretreatment of pigs with indomethacin and propranolol may also have influenced the severity of postischemic LV dysfunction (23, 25); however, any effects due to these agents would be expected in both experimental groups. Changes in myocardial glycogen and high-energy phosphate content with GIK have been measured previously and may be related to therapeutic effect in ischemia (28); however, these substances were not measured in the current study. We examined the anticipatory use of GIK (i.e., treatment begun before ischemia) but did not determine whether a similar benefit can be achieved by treatment initiated at or after the onset of ischemia.
Implications. Many patients who are admitted to hospital with unstable coronary syndromes experience early, recurrent episodes of myocardial ischemia. These episodes can cause both systolic and diastolic LV dysfunction, even in the absence of myocardial infarction and thereby contribute to morbidity and mortality. Just as such patients are treated with a combination of antianginal, antiplatelet, and anticoagulant drugs to prevent or mitigate the effects of further ischemic episodes, a strategy of anticipatory metabolic protection with GIK may also be valuable. Based on data from this study in a model of moderate myocardial ischemia without irreversible injury, the clinical benefits of GIK may extend beyond its prior application in patients with myocardial infarction to patients with intermediate coronary syndromes, such as unstable angina, who are at high risk for early, recurrent episodes of ischemia.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-49944 (G. G. Schwartz) and K08-HL-03475 (C. Greyson), a postdoctoral research fellowship of the American Heart Association, California Affiliate (L. Lu), and the Medical Research Service of the Dept. of Veterans Affairs.
| |
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: G. G. Schwartz, Cardiology Section (111B), VA Medical Center, 1055 Clermont St., Denver, CO 80220 (E-mail: Gregory.Schwartz{at}med.va.gov).
Received 6 May 1999; accepted in final form 28 September 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ahmed, S. S.,
C. H. Lee,
H. A. Oldwurtel,
and
T. J. Regan.
Sustained effect of glucose-insulin-potassium on myocardial performance during regional ischemia.
J. Clin. Invest.
61:
1123-1135,
1978.
2.
Apstein, C. S.,
F. N. Gravino,
and
C. C. Haudenschild.
Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion.
Circ. Res.
52:
515-526,
1983[Abstract].
3.
Arnott, W. M.,
D. W. Barritt,
A. S. Douglas,
B. Hunter,
A. H. Kitchin,
J. Laurie,
J. Macnon,
R. L. Richards,
R. Scarborough,
J. P. Shillingford,
I. Herland,
W. G. A. Swan,
M. P. Vessey,
W. Whitaker,
J. M. G. Wilson,
and
R. F. Fletcher.
Potassium, glucose, and insulin treatment for acute myocardial infarction.
Lancet
2:
1355-1360,
1968[ISI][Medline].
4.
Bier, J.,
B. Sharaf,
and
H. Gewirtz.
Origin of anterior interventricular vein blood in domestic swine.
Am. J. Physiol. Heart Circ. Physiol.
260:
H1732-H1736,
1991
5.
Bolli, R.
Basic and clinical aspects of myocardial stunning.
Prog. Cardiovasc. Dis.
40:
477-516,
1998[ISI][Medline].
6.
Cross, H. R.,
L. H. Opie,
G. K. Radda,
and
K. Clarke.
Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved.
Circ. Res.
78:
482-491,
1996
7.
Depre, C.,
J.-L. Vanoverschelde,
and
H. Taegtmeyer.
Glucose for the heart.
Circulation
99:
578-588,
1999
8.
Diaz, R.,
E. A. Paolasso,
L. S. Piegas,
C. D. Tajer,
M. G. Moreno,
R. Corvalan,
J. E. Isea,
and
G. Romero.
Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulin-potassium pilot trial.
Circulation
98:
2227-2234,
1998
9.
Eberli, F. R.,
E. O. Weinberg,
W. N. Grice,
G. L. Horowitz,
and
C. S. Apstein.
Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions.
Circ. Res.
68:
466-481,
1991
10.
Fath-Ordoubadi, F.,
and
K. J. Beatt.
Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials.
Circulation
96:
1152-1156,
1997
11.
Fishbein, M. C.,
S. Meerbaum,
J. Rit,
U. Lando,
K. Kanmatsuse,
J. C. Mercier,
E. Corday,
and
W. Ganz.
Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique.
Am. Heart J.
101:
593-600,
1981[ISI][Medline].
12.
Glower, D. D.,
J. A. Spratt,
J. S. Kabas,
J. W. Davis,
and
J. S Rankin.
Quantification of regional myocardial dysfunction after acute ischemic injury.
Am. J. Physiol. Heart Circ. Physiol.
255:
H85-H93,
1988
13.
Kashiwaya, Y.,
M. T. King,
and
R. L. Veech.
Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart.
Am. J. Cardiol.
80:
50A-64A,
1997[Medline].
14.
Lassers, B. W.,
L. Kaijser,
and
L. A. Carlson.
Myocardial lipid and carbohydrate metabolism in healthy, fasting men at rest: studies during continuous infusion of 3H-palmitate.
Eur. J. Clin. Invest.
2:
348-358,
1972[ISI][Medline].
15.
Laughlin, M. R.,
J. F. Taylor,
A. S. Chesnick,
and
R. S. Balaban.
Regulation of glycogen metabolism in canine myocardium: effects of insulin and epinephrine in vivo.
Am. J. Physiol. Endocrinol. Metab.
262:
E875-E883,
1992
16.
Lazar, H. L.,
X. Zhang,
S. Rivers,
S. Bernard,
and
R. J. Shemin.
Limiting ischemic myocardial damage using glucose-insulin-potassium solutions.
Ann. Thorac. Surg.
60:
411-416,
1995
17.
Lew, W. Y. W.,
and
M. M. LeWinter.
Regional comparison of midwall segment and area shortening in the canine left ventricle.
Circ. Res.
58:
678-691,
1986
18.
Lopaschuk, G. D.,
and
W. C. Stanley.
Glucose metabolism in the ischemic heart.
Circulation
95:
313-315,
1997
19.
Lu, L.,
Y. Xu,
C. R. Greyson,
P. C. Ursell,
and
G. G. Schwartz.
Non-elastic deformation of myocardium in low-flow ischemia and reperfusion: Ultrastructure-function relations.
J. Mol. Cell. Cardiol.
31:
1157-1169,
1999[ISI][Medline].
20.
Malmberg, K.,
L. Ryden,
S. Efendic,
J. Herlitz,
P. Nicol,
A. Waldenstrom,
H. Wedel,
and
L. Welin.
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.
J. Am. Coll. Cardiol.
26:
57-65,
1995[Abstract].
21.
Maroko, P. R.,
P. Libby,
B. E. Sobel,
C. M. Bloor,
H. D. Sybers,
W. E. Shell,
J. W. Covell,
and
E. Braunwald.
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion.
Circulation
45:
1160-1175,
1972
22.
Mittra, B.,
and
M. B. Agra.
Potassium, glucose, and insulin in treatment of myocardial infarction.
Lancet
2:
607-609,
1965[ISI][Medline].
23.
Mobert, J.,
and
B. F. Becker.
Cyclooxygenase inhibition aggravates ischemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes.
J. Am. Coll. Cardiol.
31:
1687-1694,
1998
24.
Nishida, H,
R. K. Grooters,
K. C. Thieman,
H. Soltanzadeh,
R. F. Schneider,
and
D. F. Merkley.
Enhanced ventricular recovery from high dose glucose, insulin and potassium with cardiopulmonary bypass support prior to cardioplegic arrest.
Eur. J. Cardiothorac. Surg.
7:
409-413,
1993[Abstract].
25.
Norris, R. M.
Beta-blockers and infarct size.
J. Mol. Cell. Cardiol.
18, Suppl. 4:
99-103,
1986.
26.
Oliver, M. F.,
and
L. H. Opie.
Effects of glucose and fatty acids on myocardial ischemia and arrhythmias.
Lancet
343:
155-158,
1994[ISI][Medline].
27.
Opie, L. H.,
K. Bruyneel,
and
P. Owen.
Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon.
Circulation
52:
49-57,
1975
28.
Opie, L. H.,
and
P. Owen.
Effect of glucose-insulin-potassium infusions on arteriovenous differences of glucose and of free fatty acids and on tissue metabolic changes in dogs with developing myocardial infarction.
Am. J. Cardiol.
38:
310-321,
1976[ISI][Medline].
29.
Rackley, C. E.,
R. O. Russell, Jr.,
W. J. Rogers,
J. A. Mantle,
H. G. McDaniel,
and
S. E. Papapietro.
Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction.
Am. Heart J.
102:
1038-1048,
1981[ISI][Medline].
30.
Rogers, W. J.,
R. O. Russell, Jr.,
H. G. McDaniel,
and
C. E. Rackley.
Acute effects of glucose-insulin-potassium infusion on myocardial substrates, coronary blood flow and oxygen consumption in man.
Am. J. Cardiol.
40:
421-428,
1977[ISI][Medline].
31.
Rogers, W. J.,
A. W. Stanley, Jr.,
J. B. Breinig,
J. W. Prather,
H. G. McDaniel,
R. E. Moraski,
J. A. Mantle,
R. O. Russell, Jr.,
and
C. E. Rackley.
Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion.
Am. Heart J.
92:
441-454,
1976[ISI][Medline].
32.
Schwartz, G. G.,
Y. Xu,
C. Greyson,
J. Cohen,
and
L. Lu.
Low-dose inotropic stimulation during left ventricular ischaemia does not worsen post-ischaemic dysfunction.
Cardiovasc. Res.
32:
1024-1037,
1996
33.
Sodi-Pallares, D.,
M. Testelli,
and
F. Fishleder.
Effects of an intravenous infusion of a glucose-potassium-insulin solution on the electrocardiographic signs of myocardial infarction.
Am. J. Cardiol.
9:
166-181,
1962[ISI][Medline].
34.
Weissler, A. M.,
R. A. Altschuld,
L. E. Gibb,
M. E. Pollack,
and
F. A. Kruger.
Effect of insulin on the performance and metabolism of the anoxic isolated perfused rat heart.
Circ. Res.
32:
108-116,
1973
35.
Wisneski, J. A.,
E. W. Gertz,
R. A. Neese,
and
M. Mayr.
Myocardial metabolism of free fatty acids. Studies with 14C labeled substrates in humans.
J. Clin. Invest.
79:
359-366,
1987.
36.
Xu, H. Y.,
J. L. Zweier,
and
L. C. Becker.
Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport.
Circ. Res.
77:
88-97,
1995
37.
Zhu, P., L. Lu, Y. Xu, and G. C. Schwartz.
Troglitazone improves recovery of ventricular function after
regional ischemia in pigs.
Circulation In press.
This article has been cited by other articles:
![]() |
L. Zhou, H. Huang, T. A. McElfresh, D. A. Prosdocimo, and W. C. Stanley Impact of anaerobic glycolysis and oxidative substrate selection on contractile function and mechanical efficiency during moderate severity ischemia Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H939 - H945. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner and R. W. Nesto Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection Circulation, May 13, 2008; 117(19): 2523 - 2533. [Full Text] [PDF] |
||||
![]() |
J. W. A. Smit and J. A. Romijn Acute insulin resistance in myocardial ischemia: causes and consequences. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 215 - 219. [Abstract] [PDF] |
||||
![]() |
G. Carvalho, A. Moore, T. Al-Backer, K. Lachapelle, and T. Schricker 26481 - CARDIOPROTECTIVE EFFECT OF INSULIN AND MAINTENANCE OF NORMOGLYCEMIA Can J Anesth, June 1, 2006; 53(suppl_1): 26481 - 26481. [Full Text] [PDF] |
||||
![]() |
D. W. Quinn, D. Pagano, and R. S. Bonser Glucose and Insulin Influences on Heart and Brain in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2005; 9(2): 173 - 178. [Abstract] [PDF] |
||||
![]() |
M. Galinanes and A. G Fowler Role of clinical pathologies in myocardial injury following ischaemia and reperfusion Cardiovasc Res, February 15, 2004; 61(3): 512 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF] |
||||
![]() |
C.J. Zuurbier Postischemic Myocardial Metabolism Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 59 - 65. [PDF] |
||||
![]() |
T. Ramanathan, K. Shirota, S. Morita, T. Nishimura, Y. Huang, and S. N. Hunyor Glucose-insulin-potassium solution improves left ventricular mechanics in diabetes Ann. Thorac. Surg., February 1, 2002; 73(2): 582 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gao, E. Gao, T.-L. Yue, E. H. Ohlstein, B. L. Lopez, T. A. Christopher, and X.-L. Ma Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial Ischemia-Reperfusion: The Roles of PI3-Kinase, Akt, and Endothelial Nitric Oxide Synthase Phosphorylation Circulation, March 26, 2002; 105(12): 1497 - 1502. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||